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Molecular interaction networks in the
analyses of sequence variation and
proteomics data
Ulrich Stelzl
Max Planck Institute for Molecular Genetics (MPIMG), Otto-Warburg Laboratory, Berlin, Germany
Protein–protein interaction networks are typically generated in standard cell lines or model
organisms as it is prohibitively difficult to record large interaction datasets from specific tissues
or disease models at a reasonable pace. Although the interaction data are of high confidence,
they thus do not reflect in vivo relationships as such. A wealth of physiologically relevant pro-
tein information, obtained under different conditions and from different systems, is available
including information on genetic variation, protein levels, and PTMs. However, these data are
difficult to assess comprehensively because the relationships between the entities remain elu-
sive from the measurements. Here, we exemplarily highlight recent studies that gained deeper
insight from genetic variation, protein, and PTMmeasurements using interaction information
pointing toward the importance and potential of interaction networks for the interpretation of
sequencing and proteomics data.
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Genotypes are expressed through regulated synthesis of en-
coded molecules, their activities and interactions. The result-
ing molecular networks involve most if not all molecules in
the cell and their physical or functional relationship. Activity
changes of genes and gene products are therefore propa-
gated through the networks in the cell. Furthermore, the cel-
lular network wiring is substantially modulated through all
sorts of intracellular, extracellular, and environmental cues.
Therefore, emergent properties of networks underlie pheno-
types [1, 2]. Even in its simplest form as nodes (represent-
ing molecules such as proteins, DNA, RNA, or metabolites)
connected through edges (representing physical interaction
or functional relationships), molecular networks represent
some of the complexity of a cell [3]. Thus a vital research goal
is to comprehensively record the molecules in cells, such
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as RNAs, proteins with its various splice and modification
states [4–7], if possible quantitatively under defined physio-
logical conditions, and to systematically map the interactions
between them [8–13].
Network properties and their correlation to disease are
being exploited in many ways [14–17]. Because of the high
connectedness and because the networks respond extensively
to intra- and extra-cellular perturbations, the differences be-
tween molecular networks of defined states will generally be
most informative for a better understanding of basic cellu-
lar processes [2] and, ultimately, of relevant alterations in a
patient individual. Therefore, network-based approaches to
human diseases focus on extracting differential networks,
thereby stripping off the static, mainly housekeeping, infor-
mation to capture the dynamic changes in cellular processes,
or tissue and disease specific alterations in networks. Unless
decent attempts will be made to consider comprehensive in-
formation of all molecules, i.e. built and learn to retrieve rele-
vant information of whole cell network models [18,19], explo-
ration of network modularity and disintegration of networks
into predictive units are apparently successful strategies to
pursue. Along this line, multiple network-based approaches
linking comprehensive molecular data records such as ge-
nomic variation, RNA expression, proteomic or posttransla-
tion modification profiles and pharmacological effects in a
disease context have been put forward. These approaches are
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referred to as network medicine [14–17] or systems/network
pharmacology [20–23] in the literature, with selected recent
achievements pointed out here.
Expression profiles and proteomic measurements now
record hundreds to thousands of differentially expressed
genes or proteins from diverse tissues or specialized dis-
ease models. In analogy to mRNA expression data, the func-
tional significance of long differential protein lists can be
interpreted through gene set enrichment analysis methods.
The methods statistically exploit precomputed annotations
[24], pathways or more comprehensively protein neighbor-
hoods [25] or protein complexes [26] to look for groups of
genes with many more members than expected. These gene
sets are then visualized as networks for better biological in-
terpretation. With the power of modern MS to very quickly
and deeply scan the differential proteomes of several tissues
or organs, these scans may be useful in monitoring com-
plex diseases or drug effects on an organismal level as al-
tered gene sets of organs are a robust indication for dysfunc-
tion [27]. Although extremely useful, these methods strictly
speaking do not use the network information in full, be-
cause the links do not contribute in the enrichment analyses.
Proteins/genes are treated as balls in anurn andnetworks and
pathway views are to display and ease the interpretation. The
actual wiring displayed had had no direct impact on the anal-
ysis that led to the result. Not so in network-based approaches
that exploit the relationships between the genes and proteins.
This principle can be illustrated by a study that established
mouse transcription factor (TF) networks through mam-
malian two-hybrid interaction screens in amodel cell line and
measured TF expression levels across a panel of 54 human
and mouse tissues. A 15 member subnetwork of interact-
ing TFs [28] involved in tissue development was established
through expression analysis also considering the differences
in expression level across TF–TF interactions. This small sub-
network was best to discriminate the expression patterns of
the cell lines very well separating tissue and stem cell types
according to their embryological origin. In this approach, the
six combinatorial interactions among TFs more than their
expression levels alone were crucial to classify tissue identity.
This suggests that relative small, however decisive, networks
could suffice to distinguish relative complex phenotypes and
that it is possible to extract them fromhighly connected global
maps that have been generated under unrelated conditions
in standard “systems biology” models.
Here, we> discuss selected studies that utilize genomics
and proteomics data (recorded on network nodes) in combi-
nation with interaction information, i.e. link information that
is typically generated in “exogenous” systems, for a better un-
derstanding of cellular machines and disease-related cellular
processes (Fig. 1). The underlying principle of all these ap-
proaches is that biologically relevant changes, often not the
strongest signals in the data, cluster in networks. Therefore
link information couples seemingly unrelated signals, which
are then and only then, recognized because their dependency
is considered.
Protein networks, in particular protein–protein interac-
tion (PPI) networks, have quickly been recognized as system-
atic framework to search for and prioritize genes with genetic
alterations in disease (Fig. 1A; for review see e.g. [14,29,30]).
Essentially, genetic and epigenetic events related to a trait
should somehow cluster in networks. With increase in cover-
age and accuracy of the networks that are used as a basis for
the disease gene predictions, studies have revealed function-
ally more consistent prioritizations in different disease fields
[30], including, e.g. neurodegeneration. The distance in a pre-
dicted physical human interaction network has been used
to prioritize candidate genes from Alzheimer’s disease (AD)
genome-wide association studies (GWAS) and suggested po-
tentially important specific linker genes [31]. Driven by inter-
action discovery experiments, a highly modular AD network
was establishedwith six GWAS candidate proteins directly in-
teracting with proteins functionally characterized in AD [32].
In general, several network-based methods are available to
prioritize mapped GWAS genes [33], however in principle
networks can conversely aid GWAS hit identification. In net-
works called susceptibility modules [34], constructed from
expression filtered PPI cliques, GWAS genes were enriched.
Such a susceptibility PPI module was constructed to analyze
seasonal allergic rhinitis-association and identified intragenic
single nucleotide polymorphisms (SNPs) within 119 genes,
which were 3.4 times more likely to be disease associated in a
cohort of 4772 individuals and led to the identification of two
new candidate genes [34].
In contrast to common genetic variants addressed in
GWAS approaches, thousands to ten thousands of rare mu-
tations and structural sequence variants in gene regions in
each individual are found through whole genome/exome
sequencing (Fig. 1A), a few of which will importantly con-
tribute to a disease [35]. The importance and functional con-
sequences of rare, sometimes even unique variants for a
disease are difficult to assess statistically. Integrative net-
work approaches have been employed to analyze the po-
tential overall impact of rare variants in certain diseases,
e.g. psychiatric disorders where GWAS did not yield many
hits. In two studies Gilman et al. used a probabilistic
human protein network to find clusters of proteins with
rare SNPs and copy number variants in patients [36, 37].
The subnetworks implicated in autism and schizophrenia
were functionally related; however the associated genetic
variants were likely functionally different for the differ-
ent diseases [36]. Although consistent pathway signals were
found, these analyses critically depend on the connectivity of
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Figure 1. Molecular interaction information leads to a better interpretation of genomic and proteomic data. Node information such
as patterns of genetic variation (A), differential protein levels and cocomplex membership (B) or changes in posttranslational protein
modifications (C) can be measured with current sequencing and MS techniques in parallel from in vivo model systems, disease models, or
patient samples (indicated by the insets representing a schematic work flow from in vivo models to sequence variation analysis and MS
approaches, respectively). Interaction information is typically recorded in exogenous model systems through AP-MS or Y2H analysis (inset
represents mammalian cell or yeast models) or inferred computationally (symbolized through standard keyboard signature in the inset)
(D). The network information provides a very useful framework to integrate specific protein data resulting in highly informative differential
networks (E) for different tissues, cellular processes or disease states.
proteins; i.e. the weighted sum of the edges is decisive for
clustering.
A recent study in yeast reported SRM-based quantitative
proteome measurements of individual yeast strains precise
enough to map quantitative protein expression variation to
single or epistatic genomic loci [7]. This suggests a proteomics
approach examining individual variation, which is in princi-
ple applicable to humans [38, 39] and would lead toward a
better understanding of the impact of genetic variation and
genetic interactions on phenotypes.
A more mechanistic approach focuses on missense mu-
tations that may alter interaction patterns of proteins. In
a proof a principle study, several disease-related missense
mutation give rise to differential protein interaction pat-
terns [40] and disease-associated missense mutations clus-
tered in interaction interfaces of proteins [41]. This is partic-
ularly striking when looking at genes that have several alleles
linked to more than one disorder as interaction patterns (ed-
getic PPI profiles) [40] and clustering of mutations in distinct
interaction interfaces [41] can explain the specificity of the dis-
ease phenotypes. TP63, e.g. harbors two distinct regions with
mutations that are associated with ectrodactyly ectodermal
dysplasia and ankyloblepharon ectodermal dysplasia, respec-
tively. The first region is in the p53-like DNA-binding domain
and the second region in the SAM2 domain, wheremutations
interfere with TP73 binding [40, 41].
Relative protein levels are routinely obtained from label
free or isotope-labeled quantification of protein samples from
different conditions or from affinity purification of biological
assemblies. Protein networks can be of very high value to bet-
ter interpret and to gainmoremechanistically understanding
of protein enrichment data from thesemass spec experiments
(Fig. 1B). In particular, integration of differential protein list
with networks (or vice versa) can provide inside into the dy-
namics of protein assemblies. For example, the spliceosomal
machinery is now in the focus of disease research as cancer
genome sequencing uncovered high frequency mutations in
several spliceosomal genes [42]. Recently, a yeast two-hybrid
(Y2H)networkwas generated providingmore than 600 binary
connections for the∼ 240 human spliceosomal proteins [43].
A set of 76 affinity purification experiments collected from a
series of proteomics studies (reviewed in [44]) was converted
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into protein–protein interaction weights and used to cluster
the Y2H data into overlapping interaction modules [45] thus
revealing dynamic interaction patterns. Central spliceosomal
proteins and their specific interactions (e.g. with hPRP8)were
identified that contribute to the exceptional compositional
dynamics—and thus function—of this large ribonucleopro-
tein machine [43]. As a second example, also targeted in vivo
affinity purification coupled to MS (AP-MS) data can provide
deeper insightwhen analyzed as networks rather than a group
of nodes or spoke expanded complexes. Twenty-four affinity
purification experiments using huntingtin (htt), the poly-
glutamine containing protein causing Huntington’s Disease,
as a bait from a knock-in mouse model resulted a protein
list of hundreds of candidate-binding proteins after standard
filtering [46]. Protein lists of this size are a typical result for
MS-based experiments and often show consistent pathway
signatures. Shirasaki et al. then constructed weighted links
between the 724 htt co-purifying proteins by pairwise
correlating peptide spectral counts over multiple conditions.
The topological overlap, a network measure for common
interaction partners of two proteins calculated from the
pairwise correlation values, was used to cluster the data into
eight htt-interactome modules, which were hierarchically
related to distinct functional aspects such as brain region
specificity, aging, and protein aggregation modulation or htt
functions directly [46].
Over the years, MS-based proteomics has recorded more
than 100 000 PTMs, such as phosphorylation, ubiquitinyla-
tion, or acetylation, across two-thirds of the human proteome
(Fig. 1C). Whether a PTM can be globally mapped is now
largely dictated by the availability of affinity tools to enrich
the modification in the samples. First studies are monitoring
specific PTMs over dynamic processes such as quantitative
measurements of phosophorylation levels over the cell
cycle [6]. Phosphorylation dynamics can be clustered in
different response behaviors, e.g. with respect to cell cycle or
early and late behaviors and displayed on protein interaction
networks [6, 47]. For example, an ataxia telangiectasia
mutated kinase driven DNA-Damage phospho-response was
put into context on the basis of PPI data, including nodes
that have not been measured, reflecting the functional orga-
nization of the signaling in terms of protein complexes and
functional network modules [47]. In another study, a directed
protein interaction network was used to model epidermal
growth factor (EGF) -dependent signal flow, i.e. EGF trig-
gered phosphorylation events, in a time-dependent manner
along outgoing links from the activated mitogen-activated
protein kinase (MAPK) pathway members in a global PPI
network [48].
Except for top-down proteomics approaches [49] and, very
recently, sequential enrichment strategies [50], where detec-
tion of covariance in modification patterns is in sight, global
modification measurement typically precludes the observa-
tion of combinatorial modifications. However, with large
datasets of different PTMs at hand, the interplay of differ-
ent types of PTMs can now be studied through data in-
tegration, and network features are emergent. Two recent
studies exploited the evolutionary conservation of PTMs re-
vealing patterns of PTM cross-talk and modification coevolu-
tion and functionality [51, 52]. All recorded modifications of
an organism were merged and the conservation of the mod-
ification sites was assessed throughout phylogeny. Statistical
significant associations of different sites revealed global net-
works of coevolving PTM types [51], likely cross-regulatory
events between distinct types of modification on a given pro-
tein [51, 52], or important sites with potential effects on pro-
tein interaction and function [52]. In addition, a few studies
are starting to assess the relationship between PTMs and pro-
tein interactions. The first large-scale studymeasuring lysine-
acetylation via MS has shown that acetylation accumulates
over protein complexes in human cultured cells [53]. A com-
putational analysis of global acetylation, phosphorylation, and
ubiquitylation data revealed different levels of coordination
of PTMs in protein interaction networks [54]. Hundreds of
protein complexes selectively accumulating PTMs were iden-
tified together with protein regions of very high PTM den-
sities. These regions, termed PTM integration spots, show
domain-like properties and likely represent sites of high reg-
ulatory potential for signaling integration. Furthermore, in
an analysis of phosphorylation sites in 26 large mitotic pro-
tein complexes that have been characterized via AP-MS [55],
proteins, with more than four phospho-sites per 100 amino
acids (switchboard subunits), were observed. A recent study
also suggested that phosphorylation-associated SNPs in can-
cer genomes may play assorted roles [56]. Together these
studies strongly emphasize network-based dataset integra-
tion as requisite in proteomic PTM studies to better predict
modification impact on cellular function.
Individual genome sequencing [35] is now reliably record-
ing rare genetic variations in gene regions. Furthermore,
expression profiling and RNA-seq comprehensively informs
about the mRNA repertoire of the cell [4], while MS-based
full proteome measurements become quantitative [5]
and targeted [57] and protein modification sites can be
measured at a large scale [6, 53]. As fast and promising
these developments are, PPI techniques are lacking that
comprehensively measure the presence, absence, or strength
of the interactions between these molecules in parallel even
for a single defined state or condition. For now, protein
interaction networks are recorded exogenously in model
systems ( [9–13], Fig. 1D) and only a few methods exist at all
that can measure interactions in intact (fixed) cells or tissues.
Thesemethods include proximity ligation assays [58], protein
complementation assays [59] and cross-linking proteomic
techniques [60]. The latter technique, which tries to reliably
identify cross-linked peptides via MS, has been used to map
interactions within and between subunits of RNA poly-
merase II [61] or protein phosphatase 2A [62] and led to better
structural interpretation of these large assemblies. In theory,
one could think of shotgun approaches using cells treated
with a cross-linking agent as input [60]. Currently, generic
high quality protein networks generated through large-scale
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screening techniques such as Y2H or AP-MS provide a major
resource for interpretation of genetic, expression, proteome,
and protein modification data. The key tasks are to integrate
specific genome/proteome measurements, assess connectiv-
ity and separate cellular processes or disease processes on the
network level. Specific subnetworks (Fig. 1E) will provide the
set of linked molecules that can be measured quantitatively
for the corresponding conditions, tissues, organs, and
ultimately in samples of individuals. In principle, current
work suggests that network guided, relatively small sets of
quantitative measurements recorded from individuals would
already be quite powerful in informing models for a more
personalized treatment of diseases.
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